Related Experiment Videos
The MCPP challenge test in schizophrenia: hormonal and behavioral responses
N Iqbal1, G M Asnis, S Wetzler
1Department of Psychiatry, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY 10467.
Abstract:
In a neuroendocrine challenge paradigm, the present study investigated responses of schizophrenic patients to m-chlorophenylpiperazine (MCPP), a serotonin (5-hydroxytryptamine, 5HT) agonist. In an oral dose of 0.25 mg/kg, MCPP was administered in a placebo-controlled double-blind design to male schizophrenic patients (n = 7) and normal male controls (n = 8). Behavioral (Positive and Negative Syndrome Scale; PANSS) and hormonal (cortisol, prolactin) variables were measured over the subsequent 210 min. The schizophrenic patients experienced an overall exacerbation of psychopathology on MCPP as compared with placebo (p less than 0.05), with specific worsening of PANSS-positive symptoms (p less than 0.025) and PANSS activation (p less than 0.001). In addition, the schizophrenic patients showed significantly lower cortisol (p less than 0.05) and prolactin (p less than 0.05) responses than the normal subjects. The schizophrenic patients had lower peak MCPP blood levels than the normal subjects, although this difference was not statistically significant. The findings are discussed in terms of 5HT receptor(s) sensitivity and the pharmacokinetics of MCPP in schizophrenia.
Insights
Schizophrenia patients showed worsened symptoms and lower hormonal responses to m-chlorophenylpiperazine (MCPP), a serotonin agonist. These findings suggest altered serotonin receptor sensitivity in schizophrenia.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Schizophrenia is a complex psychiatric disorder with significant neurobiological underpinnings.
- Serotonin (5-hydroxytryptamine, 5HT) systems are implicated in the pathophysiology of schizophrenia.
- Neuroendocrine challenge paradigms are used to probe neurotransmitter system function in psychiatric conditions.
Purpose of the Study:
- To investigate the neuroendocrine and behavioral responses to m-chlorophenylpiperazine (MCPP) in male schizophrenic patients compared to healthy controls.
- To explore the role of serotonin 5HT receptor sensitivity in schizophrenia.
Main Methods:
- A placebo-controlled, double-blind study administering MCPP (0.25 mg/kg orally) to schizophrenic patients (n=7) and normal male controls (n=8).
- Assessment of behavioral changes using the Positive and Negative Syndrome Scale (PANSS).
- Measurement of hormonal variables including cortisol and prolactin levels over 210 minutes post-administration.
Main Results:
- Schizophrenic patients exhibited an overall exacerbation of psychopathology, particularly positive symptoms and activation, after MCPP administration compared to placebo.
- Significantly lower cortisol and prolactin responses were observed in schizophrenic patients compared to controls.
- While not statistically significant, schizophrenic patients showed lower peak MCPP blood levels.
Conclusions:
- MCPP administration exacerbates psychopathology in schizophrenia, indicating potential alterations in serotonin 5HT receptor function.
- Blunted cortisol and prolactin responses suggest dysregulation of the neuroendocrine system in schizophrenia.
- The findings highlight the importance of considering serotonin system sensitivity and MCPP pharmacokinetics in schizophrenia research.